Core Insights - Aethlon Medical, Inc. will release its financial results for the fiscal second quarter ended September 30, 2025, on November 12, 2025, at 4:15 p.m. ET [1] - A conference call will be held on the same day at 4:30 p.m. ET to discuss the financial results and recent corporate developments [2] - The Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation [4] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focusing on oncology and infectious diseases [6] - The Hemopurifier has received U.S. Food and Drug Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [5] Conference Call Details - Interested parties can register for the conference call online, and those without internet access can dial in using provided toll-free numbers [2][3] - A replay of the call will be available approximately one hour after the call ends, accessible through the company's website or via specific phone numbers [4]

Core Points - Aethlon Medical, Inc. announced a public offering of 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares at a price of $0.90 per share [1] - The gross proceeds from the offering are expected to be approximately $4.5 million, which will be used for general corporate purposes including clinical trial expenses and research and development [2] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier to address needs in oncology and infectious diseases [5]